康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验

智通财经2025-12-24

智通财经APP讯，康泰生物(300601.SZ)发布公告，公司全资子公司北京民海生物科技有限公司(以下简称“民海生物”)研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗(以下简称“五联疫苗”)已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593478445?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-24 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593478445","market":"hk","top_or_hot":-1,"title":"康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康泰生物(300601.SZ)发布公告，公司全资子公司北京民海生物科技有限公司(以下简称“民海生物”)研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗(以下简称“五联疫苗”)已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385488.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-24 16:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1385488.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康泰生物(300601.SZ)发布公告，公司全资子公司北京民海生物科技有限公司(以下简称“民海生物”)研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗(以下简称“五联疫苗”)已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385488.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300601","symbol_name":"康泰生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385488.html","article_id":"2593478445","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593478445","pubTimestamp":1766566638,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康泰生物 发布公告，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","300601":"康泰生物","BK0046":"生物疫苗","BK0239":"医药制造","BK0201":"可转债"},"translate_title":"Kangtai Biotech (300601. SZ): Five-link vaccine starts phase III clinical trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"300601":1.5},"content_text":"智通财经APP讯，康泰生物(300601.SZ)发布公告，公司全资子公司北京民海生物科技有限公司(以下简称“民海生物”)研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗(以下简称“五联疫苗”)已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床研究。多联多价疫苗是行业的发展趋势，若该疫苗研发成功，将打破进口垄断，进一步丰富公司在多联苗领域的产品布局，也为六联苗等多联疫苗的研发奠定坚实基础，有利于夯实公司在联苗领域研发的领先地位，为公司持续稳健发展奠定坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593478445","isCrawlerRequest":true}